Global Eczema Therapeutics Market 2024-2028

Description

List of Tables

The eczema therapeutics market is forecasted to grow by USD 5.81 bn during 2023-2028, accelerating at a CAGR of 10.28% during the forecast period. The report on the eczema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing product launches for treating eczema, and increase in demand for over-the-counter (OTC) eczema drugs among end-users.

Technavio's eczema therapeutics market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	9.55%
CAGR	10.28%
Incremental Value	$5.81bn

By Application

Atopic dermatitis
Contact dermatitis
Other indication

By Distribution Channel

Hospital and clinics
Online pharmacies
Retail pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the rising adoption of telemedicine platforms in eczema therapeutics as one of the prime reasons driving the eczema therapeutics market growth during the next few years. Also, growing adoption of biologic therapies for eczema treatment and increasing healthcare expenditure surging demand for eczema therapeutics will lead to sizable demand in the market.

The report on the eczema therapeutics market covers the following areas:

Eczema therapeutics market sizing
Eczema therapeutics market forecast
Eczema therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics market vendors that include AbbVie Inc., Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR40707

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

4.1 Global eczema therapeutics market 2018 - 2022
4.2 Application Segment Analysis 2018 - 2022
4.3 Distribution channel Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition

6 Market Segmentation by Application

6.1 Market segments
6.2 Comparison by Application
6.3 Atopic dermatitis - Market size and forecast 2023-2028
6.4 Contact dermatitis - Market size and forecast 2023-2028
6.5 Other indication - Market size and forecast 2023-2028
6.6 Market opportunity by Application

7 Market Segmentation by Distribution Channel

7.1 Market segments
7.2 Comparison by Distribution Channel
7.3 Hospital and clinics - Market size and forecast 2023-2028
7.4 Online pharmacies - Market size and forecast 2023-2028
7.5 Retail pharmacies - Market size and forecast 2023-2028
7.6 Market opportunity by Distribution Channel

8 Customer Landscape

8.1 Customer landscape overview

9 Geographic Landscape

9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 Germany - Market size and forecast 2023-2028
9.9 UK - Market size and forecast 2023-2028
9.10 China - Market size and forecast 2023-2028
9.11 Canada - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks

12 Vendor Analysis

12.1 Vendors covered
12.2 Market positioning of vendors
12.3 AbbVie Inc.
12.4 Alliance Pharma PLC
12.5 Amneal Pharmaceuticals Inc.
12.6 AstraZeneca PLC
12.7 Bausch Health Companies Inc.
12.8 Bayer AG
12.9 Cadila Pharmaceuticals Ltd.
12.10 Eli Lilly and Co.
12.11 LEO Pharma AS
12.12 Lupin Ltd.
12.13 Merck and Co. Inc.
12.14 Novartis AG
12.15 Pfizer Inc.
12.16 Sanofi SA
12.17 Viatris Inc.

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
13.3 Currency conversion rates for US$
13.4 Research methodology
13.5 List of abbreviations